Spots Global Cancer Trial Database for Avastin for CNV Secondary to Pattern Dystrophy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Avastin for CNV Secondary to Pattern Dystrophy

Official Title: Intravitreal Avastin Injection for the Treatment of Choroidal Neovascularization Secondary to Pattern Dystrophy

Study ID: NCT00391144

Conditions

Choroidal Neovascularization Secondary to Pattern Dystrophy

Interventions

intravitreal triamcinolone injection of avastin (1.25 mg)

Study Description

Brief Summary: The natural history of subfoveal CNV secondary to Pattern Dystrophy is little understood, but it seems that visual function may be preserved only in the short-term follow-up, with progressive deterioration thereafter. Photodynamic therapy with verteporfin is the most studied therapeuthic option for this kindf of lesion, but unfortunately, this approach does not appear to guarantee long-term vision stabilization, and alternative therapies should be investigated.

Detailed Description: Diagnosis of Pattern Dystrophy Diagnosis of subfoveal CNV Intravitreal injection of avastin (1.25 mg) in operating room under sterile condition. Retreatment on the basis of the detection of disease progression and of lack of central retinal thickness reduction on OCT.